ISSUE 1233
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Insulin glulisine (Apidra – Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog)1 and insulin aspart (Novolog).2 All three have a more rapid onset and shorter duration of action than regular human insulin.3 Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.
PHARMACOKINETICS — Endogenous plasma insulin concentrations normally peak less than one hour after meals and return to baseline by 4 hours. In patients with diabetes, subcutaneous injection of regular human insulin 30 minutes before meals, the usual recommendation, results in plasma insulin concentrations that peak in 2-4 hours and remain elevated for 5-10 hours. As a result, blood glucose concentrations may be high immediately
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1233a
Electronic, downloadable article - $45